- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03571594
A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers
A Randomized, Double-blind, Placebo-Controlled, Four- Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-5788 in Healthy Adult Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This single centre study will be comprised of 4 parts, Part A (SAD; up to 7 cohorts, 8 subjects per cohort and including an assessment of food effect), a multiple-dose part (up to 4 doses, 10 subjects per cohort); an elderly cohort (8 subjects per gender) and a proof of principle part.
The single ascending dose part (Part A) comprises of increasing doses of an oral solution or capsule, with an investigation of the potential for food effects.
The multiple ascending dose part (Part B, MAD; 14 days dosing) will be initiated after the PK and safety data are available from the single ascending dose part. Subjects in Part B will have ultrasound scans of the gallbladder during the study and at screening a HIDA scan will be performed. An evaluation of the PK in the elderly and any potential gender differences will also be evaluated in Part C. Subjects in Part C will have an ultrasound of the gallbladder at screening.
Part D will be a proof of principle evaluation where the effects of ONO-5788 to inhibit the GHRH and arginine-stimulated GH release will be evaluated. Octreotide acetate is a reference arm in this part of the study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Tempe, Arizona, United States, 85283
- Celerion
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy, adult, male and female (women of non-child bearing potential, surgically sterile) volunteers, 18-55 years of age, inclusive, at screening (Parts A & B only).
- Healthy, adult, males and female (women of non-child bearing potential), ≥65 years of age at screening (Part C only).
- Healthy, adult, male, 18-40 years of age, inclusive, at screening (Part D only).
- Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECG abnormalities (All Parts).
- Body mass index (BMI) of ≥18.5 to ≤30 kg/m2 at screening (Parts A, B & C).
- Body mass index (BMI) of ≥18.5 to <25 kg/m2 at screening (Part D only).
Exclusion Criteria:
- History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
- History or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.
- History or presence of hypersensitivity or idiosyncratic reaction to the study drugs,excipients or related compounds.
History or presence of:
- Gallstones, cholangitis, and/or cholecystitis or clinically significant findings on gallbladder ultrasound as determined by the Principal Investigator;
- Pancreatitis;
- Hypothyroidism;
- Known diabetes mellitus type 1 or type 2;
- Hypocalcaemia or hypokalemia;
- Hypoglycemia or hyperglycemia or fasting blood glucose outside normal local range;
- Thrombocytopenia or other clinically significant hematologic abnormalities;
- Inflammatory bowel disease, irritable bowel syndrome, or abdominal surgery;
- Known vitamin B12 deficiency.
- Abnormal gallbladder ejection fraction on hepatobiliary iminodiacetic acid (HIDA) scan at screening (Part B only)
- Positive urine drug, alcohol or cotinine results at screening or check in.
- Clinically significant serum electrolyte (sodium, potassium, chloride, bicarbonate) abnormalities at screening or each check-in, in the estimation and clinical judgment of the PI or designee.
- Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
- Seated blood pressure is less than 90/40 millimeter of mercury (mmHg) or greater than 140/90 mmHg (160/95 mmHg for Part C) at screening.
- Has engaged in strenuous physical exercise in the 48 hours prior first dosing or intends to undergo strenuous physical exercise at any time throughout the study.
- Donation of blood or significant blood loss within 56 days prior to the first dosing.
- Plasma donation within 7 days prior to the first dosing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ONO-5788 Part A1
Single ascending doses of ONO-5788 or placebo in fasted healthy volunteers randomized 6 active : 2 placebo per group
|
Investigational drug
|
Placebo Comparator: ONO-5788 Placebo Part A1
Single ascending doses of ONO-5788 or placebo in fasted healthy volunteers randomized 6 active : 2 placebo per group
|
Placebo Comparator
|
Experimental: ONO-5788 Part A2
Single dose (1-2 groups) of ONO-5788 or placebo in healthy volunteers under fed conditions randomized 6 active : 2 placebo per group
|
Investigational drug
|
Placebo Comparator: ONO-5788 Placebo Part A2
Single dose (1-2 groups) of ONO-5788 or placebo in healthy volunteers under fed conditions randomized 6 active : 2 placebo per group
|
Placebo Comparator
|
Experimental: ONO-5788 Part B
Multiple ascending doses of ONO-5788 or placebo in healthy volunteers randomized 8 active : 2 placebo per group
|
Investigational drug
|
Placebo Comparator: ONO-5788 Placebo Part B
Multiple ascending doses of ONO-5788 or placebo in healthy volunteers randomized 8 active : 2 placebo per group
|
Placebo Comparator
|
Experimental: ONO-5788 Part C
Single doses of ONO-5788 or placebo in elderly female or elderly male healthy volunteers randomized 6 active : 2 placebo per group
|
Investigational drug
|
Placebo Comparator: ONO-5788 Placebo Part C
Single doses of ONO-5788 or placebo in elderly female or elderly male healthy volunteers randomized 6 active : 2 placebo per group
|
Placebo Comparator
|
Experimental: ONO-5788 Part D
Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
|
Investigational drug
|
Placebo Comparator: ONO-5788 Placebo Part D
Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
|
Placebo Comparator
|
Active Comparator: Octreotide Part D
Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
|
Active Comparator in Part D
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment emergent adverse events by severity
Time Frame: Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28
|
An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possible causal relationship.
|
Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28
|
Number of participants with serious adverse events (SAEs)
Time Frame: Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28
|
An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged hospitalization, life-threatening experience or persistent disability.
|
Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28
|
Number of participants with clinically significant changes in vital signs
Time Frame: Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28
|
Number of participants with clinically significant changes in vital signs including pulse/heart rate, respiratory rate, and blood pressure will be reported.
|
Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28
|
Number of participants with ECG abnormalities
Time Frame: Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28
|
Number of participants with ECG abnormalities will be reported
|
Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28
|
Number of participants with clinical laboratory abnormalities
Time Frame: Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28
|
Number of participants with clinical laboratory abnormalities will be reported
|
Part A - up to day 8; Part B - at least day 21; Part C - at least day 21; and Part D - up to day 28
|
Number of participants with clinically significant change in ultrasound of gallbladder
Time Frame: Part B - up to day 21
|
Number of participants with clinically significant change in ultrasound of gallbladder will be reported
|
Part B - up to day 21
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (AUC)
Time Frame: Day 1 through Day 14
|
Assessment of the plasma area under the curve of ONO-5788 and metabolites (Parts A, B and C only)
|
Day 1 through Day 14
|
Pharmacokinetics (AUC) - food effect
Time Frame: Day 1
|
Effect of food on the plasma area under the curve of ONO-5788 and metabolites (Parts A only)
|
Day 1
|
Pharmacokinetics (Cmax)
Time Frame: Day 1 through Day 14
|
Assessment of the maximum observed plasma concentration of ONO-5788, metabolites (Parts A, B, C & D) and octreotide (Part D only)
|
Day 1 through Day 14
|
Pharmacokinetics (Cmax) - food effect
Time Frame: Day 1
|
Effect of food on the maximum observed plasma concentration of ONO-5788, and metabolites (Part A only)
|
Day 1
|
Pharmacokinetics (Tmax)
Time Frame: Day 1 through Day 14
|
Assessment of the time to reach Cmax for ONO-5788, metabolites (Parts A, B, C & D) and octreotide (Part D only)
|
Day 1 through Day 14
|
Pharmacokinetics (Tmax) - food effect
Time Frame: Day 1 through Day 14
|
Effect of food on the time to reach Cmax for ONO-5788, metabolites (Part A only)
|
Day 1 through Day 14
|
Pharmacokinetics (Ctrough)
Time Frame: Day 1 through Day 14
|
Assessment of trough levels for ONO-5788 and metabolites immediately before dosing (Part B only)
|
Day 1 through Day 14
|
Pharmacokinetics (T1/2)
Time Frame: Day 1 through Day 14
|
Assessment of the elimination half-life of ONO-5788 and metabolites (Parts A, B and C only)
|
Day 1 through Day 14
|
Pharmacokinetics (T1/2) - food effect
Time Frame: Day 1
|
Effect of food on the elimination half-life of ONO-5788 and metabolites (metabolite) (Part A only)
|
Day 1
|
Pharmacokinetics (CL/F)
Time Frame: Day 1
|
Assessment of the apparent clearance rate of ONO-5788 (Parts A & C)
|
Day 1
|
Pharmacokinetics (CL/F) - food effect
Time Frame: Day 1
|
Effect of food on the apparent clearance rate of ONO-5788 (Part A only)
|
Day 1
|
Pharmacokinetics (Cave)
Time Frame: Day 1
|
Average concentration of ONO-5788/metabolites/Octreotide (Part D only)
|
Day 1
|
Pharmacodynamics (IGF-1)
Time Frame: Day 1 through Day 21
|
Assessment of the effects of ONO-5788 on IGF-1 levels (Part B only)
|
Day 1 through Day 21
|
Pharmacodynamics (Growth Hormone)
Time Frame: Day 1 through Day 21
|
Assessment of the effects of ONO-5788 on GH levels (Part B)
|
Day 1 through Day 21
|
Pharmacodynamics (Growth Hormone)
Time Frame: Day 1
|
Assessment of the effects of ONO-5788 on GHRH & arginine stimulated GH levels (Part D)
|
Day 1
|
Pharmacodynamics (IGFBP3)
Time Frame: Day 1 through Day 21
|
Assessment of the effects of ONO-5788 on IGFBP3 levels (Part B only)
|
Day 1 through Day 21
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Endocrine System Diseases
- Musculoskeletal Diseases
- Hypothalamic Diseases
- Bone Diseases
- Bone Diseases, Endocrine
- Hyperpituitarism
- Pituitary Diseases
- Acromegaly
- Antineoplastic Agents
- Gastrointestinal Agents
- Antineoplastic Agents, Hormonal
- Octreotide
Other Study ID Numbers
- ONO-5788-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acromegaly
-
Andrea M. IsidoriCompletedAcromegaly CardiomyopathyItaly
-
Samsung Medical CenterNot yet recruitingAcromegaly Due to Pituitary AdenomaKorea, Republic of
-
University of CopenhagenOdense University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark; Aalborg University Hospital and other collaboratorsCompletedAcromegaly Due to Pituitary AdenomaDenmark
-
Immunwork, Inc.Not yet recruiting
-
Istituto Auxologico ItalianoPolitecnico di MilanoRecruiting
-
Camurus ABCompletedAcromegalyUnited States, Spain, United Kingdom, Germany, Russian Federation, Greece, Hungary, Italy, Poland, Turkey
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Completed
-
IpsenCompletedAcromegalyGermany, Netherlands, Sweden, Czechia, Denmark, France, Greece, Italy, Spain, United Kingdom
-
Novartis PharmaceuticalsCompletedAcromegalyItaly, Australia, Belgium, Germany, Switzerland, United States, France
Clinical Trials on ONO-5788
-
Ono Pharmaceutical Co. LtdCompleted
-
Neurocrine BiosciencesImmune Tolerance Network (ITN)Completed
-
Ono Pharmaceutical Co. LtdCompleted
-
Ono Pharma USA IncCompleted
-
Ono Pharmaceutical Co. LtdCompletedVenous ThromboembolismUnited Kingdom
-
Ono Pharmaceutical Co. LtdTerminatedPain | Osteoarthritis, KneePoland, Hungary, Spain, Denmark, United Kingdom
-
Ono Pharma USA IncCompletedIrritable Bowel Syndrome (IBS)United States
-
Ono Pharma USA IncCompletedMajor Depressive DisorderUnited States
-
Ono Pharmaceutical Co. LtdCompletedOsteoarthritisDenmark, United Kingdom
-
Ono Pharmaceutical Co. LtdCompleted